“Retifanlimab Vs Avelumab in Patients With Metastatic Merkel Cell Carcinoma: A Cost Utility Analysis in Italy”. Farmeconomia. Health Economics and Therapeutic Pathways 26, no. 1 (March 13, 2025). Accessed December 28, 2025. https://journals.seedstm.com/index.php/FE/article/view/1574.